TheraRadar
Data updated: May 26, 2026

ETHACRYNATE SODIUM

Cardiovascular Approved 2015-07-29

ETHACRYNATE SODIUM is indicated for the treatment of Edema; Congestive Heart Failure; Cirrhosis; Renal Disease; Nephrotic Syndrome; Ascites; Lymphedema; Pulmonary Edema; Congenital Heart Disease.

Source: FDA Label • Viatris
4
Indications
--
Phase 3 Trials
10
Years on Market

Details

Status
Discontinued
First Approved
2015-07-29
Routes
INJECTION
Dosage Forms
INJECTABLE

ETHACRYNATE SODIUM Approval History

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
4 FDA actions from 2015 to 2020
Jun 2020 ORIGINAL
Update
Nov 2017 ORIGINAL
Update
Aug 2016 ORIGINAL
Update

What ETHACRYNATE SODIUM Treats

9 indications

ETHACRYNATE SODIUM is approved for 9 conditions since its original approval in 2015. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Edema
  • Congestive Heart Failure
  • Cirrhosis
  • Renal Disease
  • Nephrotic Syndrome
  • Ascites
  • Lymphedema
  • Pulmonary Edema
Source: FDA Label

ETHACRYNATE SODIUM Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to ETHACRYNATE SODIUM

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

EDECRIN
ETHACRYNATE SODIUM
8 shared
BAUSCH
Shared indications:
BUMETANIDE
BUMETANIDE
4 shared
ZYDUS PHARMS
Shared indications:
BUMEX
BUMETANIDE
4 shared
VALIDUS PHARMS
Shared indications:
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ETHACRYNATE SODIUM FDA Label Details

Indications & Usage

ETHACRYNATE SODIUM is indicated for the treatment of Edema; Congestive Heart Failure; Cirrhosis; Renal Disease; Nephrotic Syndrome; Ascites; Lymphedema; Pulmonary Edema; Congenital Heart Disease.

Looking for the branded version?

EDECRIN

Full clinical data, patents, trials, and competitive landscape for ethacrynate sodium.

See EDECRIN

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.